Alumis (ALMS) Competitors $3.29 -0.07 (-2.08%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.32 +0.02 (+0.76%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. KALV, ORIC, TRVI, PHAT, AVXL, XNCR, ANAB, GHRS, ABUS, and SANAShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include KalVista Pharmaceuticals (KALV), ORIC Pharmaceuticals (ORIC), Trevi Therapeutics (TRVI), Phathom Pharmaceuticals (PHAT), Anavex Life Sciences (AVXL), Xencor (XNCR), AnaptysBio (ANAB), GH Research (GHRS), Arbutus Biopharma (ABUS), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors KalVista Pharmaceuticals ORIC Pharmaceuticals Trevi Therapeutics Phathom Pharmaceuticals Anavex Life Sciences Xencor AnaptysBio GH Research Arbutus Biopharma Sana Biotechnology KalVista Pharmaceuticals (NASDAQ:KALV) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Does the media refer more to KALV or ALMS? In the previous week, KalVista Pharmaceuticals had 3 more articles in the media than Alumis. MarketBeat recorded 12 mentions for KalVista Pharmaceuticals and 9 mentions for Alumis. Alumis' average media sentiment score of 1.26 beat KalVista Pharmaceuticals' score of 1.10 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer KALV or ALMS? KalVista Pharmaceuticals currently has a consensus price target of $24.83, indicating a potential upside of 84.50%. Alumis has a consensus price target of $22.86, indicating a potential upside of 594.75%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has higher earnings and valuation, KALV or ALMS? Alumis has higher revenue and earnings than KalVista Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.62Alumis$17.39M8.93N/AN/AN/A Is KALV or ALMS more profitable? Alumis' return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -103.92% -88.06% Alumis N/A N/A N/A Does the MarketBeat Community believe in KALV or ALMS? KalVista Pharmaceuticals received 325 more outperform votes than Alumis when rated by MarketBeat users. However, 92.31% of users gave Alumis an outperform vote while only 74.73% of users gave KalVista Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes34974.73% Underperform Votes11825.27% AlumisOutperform Votes2492.31% Underperform Votes27.69% SummaryAlumis beats KalVista Pharmaceuticals on 8 of the 10 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.36M$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E RatioN/A8.7827.1220.06Price / Sales8.93255.64412.30157.10Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net IncomeN/A$143.93M$3.23B$247.88M7 Day Performance-1.79%3.84%2.86%2.63%1 Month Performance-37.33%11.20%9.07%6.36%1 Year PerformanceN/A4.18%31.45%14.05% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.9142 of 5 stars$3.29-2.1%$22.86+594.7%N/A$155.36M$17.39M0.00N/AUpcoming EarningsAnalyst UpgradeAnalyst RevisionKALVKalVista Pharmaceuticals4.0669 of 5 stars$14.12+2.3%$24.83+75.9%+10.5%$703.28MN/A-3.89100Positive NewsInsider TradeAnalyst RevisionORICORIC Pharmaceuticals3.9106 of 5 stars$9.86+7.7%$19.17+94.3%+17.2%$700.57MN/A-5.4180News CoverageAnalyst RevisionTRVITrevi Therapeutics3.5 of 5 stars$6.97+3.4%$18.63+167.1%+140.4%$696.75MN/A-15.8520PHATPhathom Pharmaceuticals4.0864 of 5 stars$9.55+103.7%$17.60+84.2%-18.0%$687.32M$81.86M-1.73110Analyst ForecastOptions VolumeHigh Trading VolumeAVXLAnavex Life Sciences3.9304 of 5 stars$8.05+3.5%$44.00+446.6%+121.6%$687.25MN/A-14.6440Positive NewsXNCRXencor4.1928 of 5 stars$9.60+5.3%$29.50+207.3%-56.6%$683.24M$127.23M-3.00280Positive NewsANABAnaptysBio1.7815 of 5 stars$23.04+9.0%$42.38+83.9%-0.2%$676.33M$111.87M-3.79100GHRSGH Research1.6525 of 5 stars$12.95+2.7%$32.00+147.1%+14.9%$673.76MN/A-16.3910Analyst RevisionABUSArbutus Biopharma2.2499 of 5 stars$3.50+2.8%$5.50+57.4%+10.1%$669.39M$6.40M-8.1390Positive NewsSANASana Biotechnology2.4752 of 5 stars$2.83+11.1%$10.80+281.2%-60.8%$652.76MN/A-2.07380Positive News Related Companies and Tools Related Companies KALV Alternatives ORIC Alternatives TRVI Alternatives PHAT Alternatives AVXL Alternatives XNCR Alternatives ANAB Alternatives GHRS Alternatives ABUS Alternatives SANA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALMS Stock Free ALMS Stock Alerts